MTOR and lymphangioleiomyomatosis: Intriguingly, this is comparable to a human age of approximately 40–50 years (43, 44), the average age of respiratory failure in patients with LAM requiring initiation of the allosteric mTOR inhibitor rapamycin (sirolimus) (45).